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Golden color imparted by carotenoid pigments is the eponymous feature of the human 
pathogen 
 
Staphylococcus aureus
 
. Here we demonstrate a role of this hallmark phenotype in 
virulence. Compared with the wild-type (WT) bacterium, a 
 
S. aureus
 
 mutant with disrupted 
carotenoid biosynthesis is more susceptible to oxidant killing, has impaired neutrophil 
survival, and is less pathogenic in a mouse subcutaneous abscess model. The survival 
advantage of WT 
 
S. aureus
 
 over the carotenoid-deficient mutant is lost upon inhibition of 
neutrophil oxidative burst or in human or murine nicotinamide adenine dinucleotide 
phosphate oxidase–deficient hosts. Conversely, heterologous expression of the 
 
S. aureus
 
 
carotenoid in the nonpigmented 
 
Streptococcus pyogenes
 
 confers enhanced oxidant and 
neutrophil resistance and increased animal virulence. Blocking 
 
S. aureus
 
 carotenogenesis 
increases oxidant sensitivity and decreases whole-blood survival, suggesting a novel target 
for antibiotic therapy.
 
Ogston coined the genus 
 
Staphylococcus
 
 to de-
scribe grapelike clusters of bacteria (
 
staphylo
 
means 
 
grape
 
 in Greek) recovered in pus
from surgical abscesses (1). Shortly thereaf-
ter, Rosenbach isolated the major human
pathogen in pure culture and proposed
the species name 
 
S. aureus
 
 (golden, in Latin)
for its characteristic surface pigmentation in
comparison with less virulent staphylococci
that normally colonize the skin surface (2).
Subsequent studies of the 
 
S. aureus
 
 pigment
have unraveled an elaborate biosynthetic
pathway that produces a series of carotenoids
(3). Similar carotenoids produced in dietary
fruits and vegetables are well recognized as po-
tent antioxidants by virtue of their free-radical
scavenging properties and exceptional ability
to quench singlet oxygen (4, 5). We hypoth-
esized that 
 
S. aureus
 
 could utilize its golden
carotenoid pigment to resist oxidant-based
clearance  mechanisms of the host innate im-
mune system. Here we apply a molecular ge-
netic approach of targeted mutagenesis and
heterologous expression, coupled with in vitro
and in vivo models of bacterial pathogenesis,
to demonstrate that the 
 
S. aureus
 
 pigment is a
virulence factor and potential novel target
for antimicrobial therapy.
 
RESULTS AND DISCUSSION
Mutagenesis, complementation, and 
heterologous expression of 
 
S. aureus
 
 pigment
 
The biosynthetic pathway for 
 
S. aureus
 
 carot-
enoids (6) includes the essential functions of
genes 
 
crt
 
M and 
 
crt
 
N, encoding dehydrosqualene
synthase and dehydrosqualene desaturase,
respectively (Fig. 1 A). To probe the biolog-
ical activities of the 
 
S. aureus
 
 pigment, we
generated an isogenic mutant of a golden-
colored human clinical isolate by allelic re-
placement of 
 
crt
 
M (Fig. 1 A). Consistent
with previous reports, pigmentation of the
WT strain became apparent in the early sta-
tionary phase of growth and continued to
intensify before reaching a plateau at 36–48 h
(Fig. 1 B). The 
 
 
 
CrtM mutant was non-
pigmented and lacked the characteristic triple-
peak spectral profile of WT carotenoid at
440-, 462-, and 491-nM wavelengths (Fig. 1
B). No differences in growth rate, stationary
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phase density, surface charge, buoyancy, or hydrophobicity
were observed between WT and 
 
 
 
CrtM 
 
S. aureus
 
 (Fig.
S1, A–D, available at http://www.jem.org/cgi/content/
full/jem.20050846/DC1). 
 
S. aureus crt
 
M and 
 
crt
 
N together
are sufficient for production of 4,4
 
 
 
-diaponeurosporene
(3). To facilitate gain of function analyses, we expressed
both genes in the nonpigmented 
 
Streptococcus pyogenes
 
, a
human pathogen associated with a disease spectrum similar
to that of 
 
S. aureus
 
. When transformed with the pCrtMN
plasmid, 
 
S. pyogenes
 
 gained yellow pigmentation (Fig. 1
B) with the spectral characteristics of a carotenoid (not
depicted). Complementation of the 
 
S. aureus
 
 
 
 
 
CrtM mu-
tant with pCrtMN vector also fully restored pigmentation
(Fig. 1 B).
 
S. aureus
 
 pigment functions as an antioxidant
 
One important mechanism by which phagocytic cells elimi-
nate pathogens is through release of reactive oxygen species
generated by nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase (7). It has been suggested that bacterial
carotenoids such as those expressed by 
 
S. aureus
 
 could serve a
protective function against these defense molecules (8–10).
To prove this thesis experimentally, we first compared the
susceptibility of WT and 
 
 
 
CrtM 
 
S. aureus
 
 to oxidants in
vitro. As shown in Fig. 1, C and D, the 
 
 
 
CrtM mutant was
killed more efficiently by hydrogen peroxide and singlet ox-
ygen compared with the WT 
 
S. aureus
 
 strain. Complemen-
tation with pCrtMN restored the ability of the 
 
 
 
CrtM mu-
tant to resist singlet oxygen killing (Fig. 1 D). Similarly,
Figure 1. Genetic manipulation of S. aureus carotenoid pigment 
and its antioxidant function. (A) Biochemical pathway for S. aureus 
carotenogenesis and mutagenesis of crtM (encoding dehydrosqualene 
synthase) by allelic replacement. (B) Elimination of S. aureus pigmentation 
in  crtM mutant; heterologous expression of S. aureus 4,4 -diaponeuro-
sporene pigment in Streptococcus pyogenes. Increased susceptibility of 
the S. aureus  CrtM mutant to killing by (C) hydrogen peroxide or (D) 
singlet oxygen, with restoration of WT resistance levels upon comple-
mentation with pCrtMN. (E) Decreased singlet oxygen susceptibility of S. 
pyogenes expressing 4,4 -diaponeurosporene. Results shown are repre-
sentative of at least three repeated experiments. Error bars, SD of 
depicted variable performed in duplicate or triplicate. 
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heterologous expression of staphylococcal pigment in 
 
S.
pyogenes
 
 led to a significant decrease in susceptibility to sin-
glet oxygen (Fig. 1 E).
 
S. aureus
 
 pigment confers resistance to neutrophil 
and whole-blood killing
 
We next sought to determine whether the observed antioxi-
dant activity of the 
 
S. aureus
 
 carotenoid translated to in-
creased bacterial resistance to innate immune clearance using
two ex vivo assay systems: human or mouse whole-blood
survival and coculture with purified human neutrophils. WT
 
S. aureus
 
 survived significantly better than the nonpigmented
 
 
 
CrtM intracellularly within human neutrophils (Fig. 2 A
and Fig. S2 F, available at http://www.jem.org/cgi/content/
full/jem.20050846/DC1) and in whole blood of normal
mice or human donors (Fig. 2, B and E). The former effect
was not explained by differences in the rate of phagocytosis,
because uptake of the WT 
 
S. aureus
 
 and 
 
 
 
CrtM mutant was
comparable (Fig. S2 A). Nor were differences attributable to
changes in the magnitude of neutrophil oxidative burst, be-
cause uptake of WT and mutant strains produced similar
results in a nitroblue tetrazolium reduction assay (Fig. S2 B).
Complementation of the 
 
S. aureus
 
 
 
 
 
CrtM mutant with
pCrtMN restored resistance to killing by mouse whole blood
(Fig. 2 B). Likewise, the pigmented 
 
S. pyogenes
 
 expressing
staphylococcal carotenoid showed enhanced survival in hu-
man neutrophils versus the parent strain (Fig. 2 C).
To verify that the association of 
 
S. aureus
 
 carotenoid ex-
pression with enhanced phagocyte resistance was a direct
consequence of its antioxidant properties, assays were re-
peated in the presence of the oxidative burst inhibitor diphe-
nyleneiodonium (DPI). WT and 
 
 
 
CrtM 
 
S. aureus
 
 survived
equally well in human neutrophils (Fig. 2 D) and mouse
blood (Fig. S2 C) when oxidative burst was inhibited by
DPI. Gp47
 
Phox
 
 
 
/
 
 
 
 is an inherited defect in phagocyte oxida-
tive burst function commonly found in patients who have
chronic granulomatous disease (CGD), and the gp91
 
Phox
 
 
 
/
 
 
 
mouse represents a model of human X-linked CGD (11).
The survival advantage of WT over nonpigmented 
 
 
 
CrtM
 
S. aureus
 
 was evident only in the blood of normal humans
and mice (CD1 or C57Bl/6), and not in the blood of a human
gp47
 
phox
 
 
 
/
 
 
 
 patient or gp91
 
Phox
 
 
 
/
 
 
 
 mice lacking NADPH
oxidase activity (Fig. 2, E and F).
It was recently reported that the apparent neutrophil kill-
ing of pathogens by reactive oxygen species could largely re-
flect the activation of granule proteases mediated through
changes in potassium flux (12). We found no difference in
the susceptibility of WT and 
 
 
 
CrtM 
 
S. aureus
 
 to the antimi-
crobial action of cathepsin G, and both strains were resistant
to human neutrophil elastase as previously observed for 
 
S.
aureus
 
 (13) (Fig. S2 D). Other effector molecules of mamma-
lian neutrophils critical to innate immune defense are the
cathelicidin family of antimicrobial peptides (14). The ca-
rotenoid-deficient 
 
S. aureus
 
 mutant was equally susceptible
to killing by the murine cathelicidin mCRAMP when com-
pared with the WT strain (Fig. S2 E). These results support
a primary role for the free-radical scavenging antioxidant
properties of the 
 
S. aureus
 
 carotenoid in resistance to neutro-
phil-mediated killing.
 
S. aureus
 
 pigment contributes to virulence 
in a subcutaneous abscess model
 
Our in vitro and ex vivo results demonstrate that 
 
S. aureus
 
 ca-
rotenoid is both necessary and sufficient to promote oxidant
resistance and phagocyte survival. To assess the significance of
these observations to disease pathogenesis, we used a murine
subcutaneous challenge model. In these studies, individual ani-
mals were injected simultaneously in one flank with the WT 
 
S.
aureus
 
 strain and in the opposite flank with the 
 
 
 
CrtM mutant.
At the site of WT injection (10
 
6
 
 CFU), mice developed size-
Figure 2. S. aureus carotenoid pigment confers resistance to oxi-
dant killing in neutrophils and whole blood. Survival of WT and  CrtM 
S. aureus in (A) coculture with isolated human neutrophils and (B) murine 
whole blood. Also shown in B is whole-blood survival of  CrtM comple-
mented with vector alone or pCrtMN. (C) Effect of plasmid expression of 
crtMN on survival of Streptococcus pyogenes in mouse whole blood. 
(D) Effect of oxidative burst inhibitor DPI on survival of WT and  CrtM 
mutant S. aureus human neutrophil coculture. Relative survival of WT and 
 CrtM mutant S. aureus is shown in (E) normal human and gp47phox /  
patient lacking NADPH oxidase function or (F) the blood of WT CD1 and 
C57Bl/6 mice and gp91Phox /  mice. Results shown are representative of 
at least three repeated experiments, except for assay using blood from the 
CGD human patient, which was performed twice. Error bars, SD of de-
picted variable performed in duplicate or triplicate.S. AUREUS PIGMENT AND VIRULENCE | Liu et al. 212
able abscess lesions reaching a cumulative size of 80 mm2 by
d 4; injection of an equivalent inoculum of the carotenoid-
deficient mutant on the contralateral flank failed to produce
visible lesions (Fig. 3 A). Quantitative culture from skin le-
sions at two different challenge doses (106 CFU to 107 CFU)
consistently demonstrated significantly higher numbers of
surviving WT S. aureus compared with the  CrtM mutant
in the individual mice (Fig. 3 A). To corroborate that an an-
tioxidant effect is key to the mechanism of protection af-
forded by the S. aureus carotenoid in vivo, the subcutaneous
infection experiment was repeated in gp91Phox /  mice. In
the absence of host NADPH oxidase function, WT and
 CrtM mutant S. aureus produced lesions of similar cumula-
tive size, and no survival advantage was detected on quanti-
tative abscess culture (Fig. 3 B). Finally, we asked whether S.
aureus carotenoid was sufficient to enhance bacterial viru-
lence by comparing the course of infection produced by S.
pyogenes expressing CrtMN with that in controls transformed
with vector alone. As shown in Fig. 3 C, lesions generated
by the carotenoid-expressing strain were significantly larger
and contained greater numbers of surviving bacteria than
those produced by the WT strain. Raw data from the in
vivo experiments are provided in Table S1 (available at http:
//www.jem.org/cgi/content/full/jem.20050846/DC1).
Figure 3. S. aureus carotenoid contributes to virulence in a subcu-
taneous abscess model. Mice were injected subcutaneously in opposite 
flanks with the two bacterial strains under comparison. Line graphs depict 
sum cumulative skin lesion size generated by the indicated bacterial strain. 
Dots on scatter graphs indicate ratio of CFU of pigmented versus nonpig-
mented strains recovered from skin lesions in each individual mouse. Pho-
tographic image depicts representative mouse in each treatment group. 
(A) WT versus  CrtM mutant S. aureus in CD1 mice. (B) WT versus  CrtM 
mutant S. aureus in gp91Phox /  mice. (C) Streptococcus pyogenes   
expression of staphylococcal 4,4 -diaponeurosporene.JEM VOL. 202, July 18, 2005 213
BRIEF DEFINITIVE REPORT
S. aureus pigment production is a potential novel target 
for antimicrobial therapy
Given the protective effect provided to the bacteria by the
golden yellow pigments, we examined whether a pharmaco-
logic agent that inhibited carotenogenesis might render S.
aureus more susceptible to immune clearance. The mixed
function oxidase inhibitor 2-diethylaminoethyl-2,2-diphe-
nyl-valerate (SKF 525-A; Calbiochem) was previously
shown to inhibit pigment formation in S. aureus (15), al-
though a moderate residual accumulation of   carotenoid in-
termediate was noted in those experiments. As shown in Fig.
4 A, we found a dose-dependent decrease in pigment pro-
duction in our WT strain of S. aureus grown in the presence
of this agent. Blocking S. aureus pigment formation led to a
dose-dependent increase in the susceptibility of the organism
to singlet oxygen killing (Fig. 4 B) and a decrease in the abil-
ity of WT S. aureus to survive in murine whole blood (Fig. 4
C). As a control, the  CrtM mutant was exposed to SKF
525-A in parallel experiments with no significant effects on
oxidant susceptibility or blood survival (Fig. 4, B and C).
Golden color imparted by carotenoid pigments is the
eponymous feature of the human pathogen S. aureus. We
have used a molecular genetic analysis pairing mutagenesis and
heterologous expression to show that this hallmark phenotype
is in fact a virulence factor, serving to protect the bacterium
from phagocytic killing through its antioxidant properties. In
the present era, effective control of this important disease
agent is compromised by rapid evolution of antimicrobial re-
sistance in both community and hospital settings (16, 17). In
principle, the inhibition of carotenogenesis may offer a novel
therapeutic approach to the treatment of complicated S. aureus
infections, effectively rendering the pathogen more susceptible
to clearance by normal host innate immune defenses.
MATERIALS AND METHODS
Bacteria, mice, and chemical reagents. WT S. aureus strain (Pig1),
isolated from the skin of a child with atopic dermatitis, was a gift from D.
Leung (National Jewish Medical and Research Center, Denver, CO). S.
pyogenes strain 5448 is a well-characterized serotype M1T1 clinical isolate
(18). CD1 and C57Bl/6 mice were purchased from Charles River Labo-
ratories. The gp91Phox /  mice were bred at the Veteran’s Administration
Medical Center, San Diego, CA, and maintained on trimethoprim/sul-
famethoxazole prophylaxis until 3 d before experiments. S. aureus and S.
pyogenes were propagated in Todd-Hewitt broth (THB) or on THB agar
(Difco). Unless otherwise indicated, all experiments were performed with
bacteria derived from light-protected S. aureus 36–48-h stationary phase
cultures or S. pyogenes 24-h stationary phase cultures, a point at which
pigmentation phenotypes were readily apparent.
Human CGD patient. The human CGD patient was an 18-yr-old fe-
male with a gp47phox deficiency (homozygous  GT deletion in exon 2). At
the time of study, she was in good health, and her only medication was IFN 
(50  g/m2) administered three times per wk by subcutaneous injection.
Generation of the carotenoid-deficient S. aureus mutant,  CrtM.
Precise, in-frame allelic replacement of the S. aureus crtM gene with a
chloramphenicol acetyltransferase (cat) cassette was performed using PCR-
based methods as described for S. pyogenes (19) or Streptococcus agalactiae
(20), with minor modifications. Primers were designed based on the pub-
lished S. aureus crtMN sequence (6) cross-referenced to genome S. aureus
strain N315 (21). PCR was used to amplify  500 bp upstream of crtM
with primers crtMupF 5 -TTAGGAAGTGCATATACTTCAC-3  and
crtMstartR 5 -GGTGGTATATCCAGTGATTTTTTTCTCCATAC-
TAGTCCTCCTATATTGAAATG-3 , along with  500 bp of sequence
immediately downstream of crtM with primers crtMendF 5 -TAC-
TGCGATGAGTGGCAGGGCGGGGCGTAACAAAGTATTTAGTA-
TTGAAGC-3  and crtMdownR 5 -GGCACCGTTATACGATCATCGT-
3 . The crtMstartR and crtMendF primers were constructed with 25-bp 5 
extensions corresponding to the 5  and 3  ends of the cat gene, respec-
tively. The upstream and downstream PCR products were then combined
with a 650-bp amplicon of the complete cat gene (from pACYC184) as
templates in a second round of PCR using primers crtMupF and crtM-
downR. The resultant PCR amplicon, containing an in-frame substitution
of crtM with cat, was subcloned into temperature-sensitive vector pHY304
to create the knockout plasmid. This vector was transformed initially into
permissive S. aureus strain RN4220 (provided by P. Sullam (Veteran’s Af-
fairs Medical Center, San Francisco, CA) and then into S. aureus strain
Pig1 by electroporation. Transformants were grown at 30 C, shifted to the
nonpermissive temperature for plasmid replication (40 C), and differential
antibiotic selection and pigment phenotype were used to identify candi-
date mutants. Allelic replacement of the crtM allele was confirmed unam-
biguously by PCR reactions documenting targeted insertion of cat and ab-
sence of crtM in chromosomal DNA isolated from the final mutant
 CrtM.
Complementation and heterologous expression studies. Primers
CrtF 5 -CAGTCTAGAAATGGCATTTCAATATAGGAG-3  and CrtR
5 -ATCGAGATCTCTCACATCTTTCTCTTAGAC-3  were used to
amplify the contiguous CrtM and CrtN genes from the chromosome of
WT S. aureus strain Pig1. The fragment was directionally cloned into the
shuttle expression vector pDCerm (19) and the recombinant plasmid
(pCrtMN) used to transform by electroporation the S. aureus  CrtM mu-
tant and S. pyogenes strain 5448. All stocks of pCrtMN-transformed S. pyog-
enes were destroyed by autoclaving at the conclusion of the project.
Figure 4. Inhibition of S. aureus pigment production increases oxi-
dant sensitivity and phagocytic clearance. WT and  CrtM mutant 
S. aureus were cultured in the presence or absence of SKF 525-A at the indi-
cated concentrations. Depicted are the observed effects on (A) pigmentation 
phenotype, (B) singlet oxygen susceptibility, and (C) survival in murine whole 
blood. Results shown are representative of at least three repeated experi-
ments. Error bars, SD of depicted variable performed in duplicate or triplicate.S. AUREUS PIGMENT AND VIRULENCE | Liu et al. 214
Spectral profile of the S. aureus carotenoid. Stationary phase (48-h)
cultures of WT S. aureus Pig1 and its isogenic  CrtM mutant were sub-
jected to methanol extraction. The absorbance profile of the extracts was
measured with a MBA 2000 spectrophotometer (PerkinElmer).
Oxidant susceptibility assays. Tests for susceptibility to oxidants were
performed either in PBS (S. aureus) or THB (S. pyogenes). Hydrogen perox-
ide (H2O2) was added to 1.5% final concentration, 2   09 bacteria were in-
cubated at 37 C for 1 h, and then 1,000 U/ml of catalase (Sigma-Aldrich)
was added to quench residual H2O2. Dilutions were plated on Todd-Hewitt
agar (THA) for enumeration of surviving CFU. For the singlet oxygen as-
say, 108 S. aureus or 4   108 S. pyogenes were incubated at 37 C in individ-
ual wells of a 24-well culture plate in the presence or absence of 1–6  g/ml
methylene blue and situated exactly 10 cm from a 100-W light source. Bac-
terial viability was assessed after 1–3 h by plating dilutions on THA. Control
plates handled identically but wrapped in foil or exposed to light in the ab-
sence of methylene blue did not show evidence of bacterial killing.
Whole-blood killing assays. Bacteria were washed twice in PBS, diluted
to an inoculum of 104 CFU in 25  l PBS, and mixed with 75  l of freshly
drawn human or mouse blood in heparinized tubes. The tubes were incu-
bated at 37 C for 4 h with agitation, at which time dilutions were plated on
THA for enumeration of surviving CFU.
Neutrophil intracellular survival assays. Neutrophils were purified
from healthy human volunteers using a Histopaque gradient (Sigma-
Aldrich) per manufacturer’s directions. Intracellular survival assays were
performed as follows. Bacterial cultures were washed twice in PBS, diluted
to a concentration of 4.5   106 CFU in 100  l RPMI 1640   10% FCS
and mixed with 3   105 neutrophils in the same media (multiplicity of in-
fection   15:1), centrifuged at 700 g for 5 min, then incubated at 37 C in a
5% CO2 incubator. Gentamicin (final concentration 400  g/ml for S. au-
reus and 100  g/ml for S. pyogenes; GIBCO BFL) was added after 10 min to
kill extracellular bacteria. At specified time points, the contents of sample
wells were withdrawn, centrifuged to pellet the neutrophils, and washed to
remove the antibiotic medium. Neutrophils were then lysed in 0.02% Tri-
ton X, and CFU were calculated by plating on THA. Several assays were
repeated with the addition of a step involving preincubation of the bacterial
inoculum with 10% autologous human serum for 15 min on ice.
Murine model of subcutaneous infection. 10–16-wk-old CD-1 or
gp91Phox /  mice were injected subcutaneously in one flank (chosen ran-
domly) with the bacterial test strain and simultaneously in the opposite flank
with a different strain for direct comparison. Bacterial cultures were washed,
diluted, and resuspended in PBS mixed 1:1 with sterile Cytodex beads (GE
Healthcare) at the specified inoculum, following an established protocol for
generating localized S. aureus and S. pyogenes subcutaneous infection (14, 22).
Lesion size, as assessed by the maximal length   width of the developing ul-
cers, was recorded daily. Cumulative lesion size represents the total sum of
lesion sizes from all animals in each treatment group on a given day. At day 8
(S. aureus) or day 5 (S. pyogenes), animals were killed, and skin lesions were
excised, homogenized in PBS, and plated on THA for quantitative culture.
Statistics. The significance of experimental differences in oxidant sensitiv-
ity, blood killing, and neutrophil survival were evaluated by unpaired Stu-
dent’s t test. Results of the mouse in vivo challenge studies were evaluated
by paired Student’s t test.
Assurances. All animal experiments were approved by the University of
California, San Diego (UCSD) Committee on the Use and Care of Animals
and performed using accepted veterinary standards. Experimentations using
human blood were approved by the Dual Tracked UCSD Human Re-
search Protection Program/CHSD IRB. Prior informed consents were ob-
tained from the human subjects. Experimental protocols were approved by
the UCSD Biosafety Committee.
Online supplemental material. Fig. S1 provides basic characterization
of the WT and  CrtM mutant S. aureus isolates in terms of growth rate,
buoyancy, hydrophobicity, and surface charge. Fig. S2 contains data com-
paring WT and DCrtM mutant S. aureus with respect to rate of phagocytic
uptake in neutrophils, induction of neutrophil oxidative burst, mouse
whole-blood survival with and without NADPH oxidase inhibition, sensi-
tivity to granule proteases and cationic antimicrobial peptides, and survival
in human neutrophils after preopsonization. Table S1 contains detailed data
on lesion size and bacterial counts from the in vivo mouse challenge exper-
iments shown in Fig. 3. A brief supplemental Materials and methods section
is provided for those experiments appearing only in the supplemental fig-
ures. Online supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20050846/DC1.
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